Drugs & Therapy Perspectives

, Volume 28, Issue 10, pp 6–11 | Cite as

Fingolimod: a guide to its use in multiple sclerosis in the EU

  • Lesley J. Scott
  • Katherine A. Lyseng-Williamson
Adis Drug Clinical Q&A
  • 42 Downloads

Abstract

Fingolimod, a novel sphingosine 1-phosphate receptor agonist, is indicated for the treatment of patients with relapsing- remitting multiple sclerosis. In clinical trials, oral fingolimod was more effective than placebo and intramuscular interferon β-1a at reducing annualized relapse rates and the burden and activity of disease.

Keywords

Basal Cell Carcinoma Macular Oedema Natalizumab Glatiramer Acetate Fingolimod 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs 2011; 25 (8): 673–98PubMedCrossRefGoogle Scholar
  2. 2.
    Gilenya: summary of product characteristics. London: European Medicines Agency, 2012 Jul 6Google Scholar
  3. 3.
    Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362 (5): 387–401PubMedCrossRefGoogle Scholar
  4. 4.
    Haas J, Hartung HP, Von Rosenstiel P, et al. Effect of fingolimod on severe multiple sclerosis relapses, healthcare utilization and recovery: results from two phase 3 studies, TRANSFORMS and FREEDOMS [abstract plus poster. no P06.049]. 63rd Annual Meeting of the American Academy of Neurology; 2011 Apr 9–16; Honolulu (HI)Google Scholar
  5. 5.
    Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362 (5): 402–15PubMedCrossRefGoogle Scholar
  6. 6.
    Calabresi PA, Radue E-W, Goodin D, et al. Efficacy and safety of fingolimod in patients with relapsing remitting multiple sclerosis (RRMS): results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II study) [poster no. E-002]. 64rd Annual Meeting of the American Academy of Neurology; 2012 Apr 21–28; New Orleans (LA)Google Scholar
  7. 7.
    Cohen J, Barkhof F, Comi G, et al. Oral fingolimod (FTY720) treatment improves the performance of daily activities compared with intramuscular interferon β-1a: Patient-Reported Indices for Multiple Sclerosis (PRIMUS)-Activities results from a phase III study (TRANSFORMS) [abstract no. P06.137]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)Google Scholar
  8. 8.
    Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011; 10 (6): 520–9PubMedCrossRefGoogle Scholar
  9. 9.
    Izquierdo G, O’Connor P, Montalban X, et al. Long-term fingolimod (FTY720) in relapsing MS: 5 years results from an extension of a phase II, multicenter study show a sustained low level of disease activity [abstract plus poster no. PD6.004]. 63rd Annual Meeting of the American Academy of Neurology; 2011 Apr 9–16; Honolulu (HI)Google Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Lesley J. Scott
    • 1
  • Katherine A. Lyseng-Williamson
    • 1
  1. 1.AdisAucklandNew Zealand

Personalised recommendations